Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027
The global Immunoassay Market in terms of revenue was estimated to be worth $40.2 billion in 2022 and is poised to reach $49.6 billion by 2027, growing at a CAGR of 4.3% from 2022 to 2027. Market growth is driven by the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, and growth in the biotechnology and biopharmaceutical industries.
To know about the assumptions considered for the study, Request for Free Sample Report
Immunoassay Market Dynamics
Drivers: Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
The burden of chronic diseases, along with the massive infection rate and the COVID-19 pandemic, has necessitated the use of immune-diagnostic assays for containment and management. Immunoassay tests are considered an essential diagnostic tool that offers reliable and low-cost detection of pathogens or target molecules. These tests are used to diagnose both highly prevalent and chronic diseases.
On a global scale, immunoassays have become the frontline diagnostics for detecting several pathogens and pathophysiological conditions. The increasing demand for the early-stage diagnosis of disease conditions using immunoassay products is another major factor driving the market growth.
Globally, the number of diabetics is expected to grow from 643 million in 2030 to 783 million by 2045. Diabetes resulted in 6.7 million deaths worldwide in 2021, while 541 million people are estimated to be at risk of developing diabetes (Source: International Diabetes Federation).
The WHO underlined the global concern of HIV, which has claimed over 33 million lives; an estimated 38 million people have HIV infections. Similarly, The International Agency for Research on Cancer and GLOBOCAN estimated 19.3 million new cases of cancer and 10.0 million deaths in 2020. Breast cancer dominates this estimate with 2.3 million new cases, followed by lung, colorectal, prostate, and stomach cancer.
Opportunities: Advancements in systems and technologies
Key players and researchers have several advanced, reliable, and economic immunoassay platforms for disease diagnostics. Automated systems offer flexibility in scale-up, massive sampling volume, faster processing, vast storage, and high efficacy required for COVID-19 diagnosis and management. Recent developments in this market include:
- In September 2021, Thermo Fisher Scientific, Inc. (US) launched its fully automated analyzers, Thermo Scientific Gallery Enzyme Master and Thermo Scientific Gallery Plus Enzyme Master, which are specifically designed for enzyme assay applications.
- In May 2021, Beckman Coulter (US) launched its fully automated and qualitative COVID-19 immunoassay, Access SARS-CoV-2 IgG (1st IS). The immunoassay is a fully quantitative lab-based Immunoglobulin G (IgG) serology test intended to measure the number of antibodies against the virus that causes COVID-19.
- In February 2021, F. Hoffmann-La Roche (Switzerland) launched the SARS-CoV-2 Rapid Antigen Test Nasal with patient self-collection.
Other important areas are rapid immunoassays, decentralized and near-patient point-of-care (POC) assays, and lateral flow assays that enable assays to be accessed by patients without sophisticated instruments. Nanozymes—enzyme-like nanomaterial mimicking catalase, oxidase, and peroxidase—are also emerging technologies utilized as alternatives to natural enzymes used in ELISA and biosensing.
Challenges: Technical hurdles of immunoassay kits a key restraining factor limiting the growth of market
There are several disadvantages associated with immunoassays. Cross-reactivity has been a constant element challenging the reliability and specificity of the immunoassays. Antibodies bind with the structural analogs of the target antibody/analyte in immunoassays. Other issues involve the need for high sample volumes for detection, complex workflows, unsuitability for high-throughput screening analysis (ELISA), and reagent instability.
The routine colorimetric readout ELISA is not considered suitable for low-concentration analytes or target molecules. Immunoassays are not considered specific assays for the diagnosis of viral RNA sequences. They have been observed to have issues associated with detecting certain biomolecules such as non-specific IgM, rheumatoid factor, and interferons.
Immunoassays are also associated with false negatives during the early stage of the infection. This inaccurate sensitivity is a challenge among the mildly symptomatic to asymptomatic who have a low titer of antibodies in response to the coronavirus infection.
Immunoassay Market Ecosystem
“In 2021, kits reagents segment accounted for the largest share of the immunoassay market, by product”
The global immunoassay market is segmented into reagents kits and analyzers based on product. Market growth is largely driven by the high consumption and frequent purchases of reagents kits coupled with the rise in the number of immunoassay tests performed across the globe.
In 2021, ELISA accounted for the largest share in the immunoassay market, by technology”
The global market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. ELISA accounted for the largest share of the global market in 2021. The large share of this technology segment can primarily be attributed to the increasing use of ELISA tests in cancer diagnosis, infectious diseases detection, and therapeutic drug level monitoring.
In 2021, blood specimen segment accounted for the largest share in the immunoassay market, by specimen”
Based on specimens, the global market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens accounted for the largest share of the global market, primarily due to the rising incidence of chronic and infectious diseases.
“In 2021, infectious diseases segment accounted for the largest share of the immunoassay market, by application”
The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. Rising prevalence of infectious diseases and increase in the number of products launches catering to infectious disease diagnosis to drive growth of the segment.
In 2021, hospitals clinics accounted for the largest share in the immunoassay market, by end user”
The global market is segmented into hospitals clinics, clinical laboratories, pharmaceutical biotechnology companies and CROs, blood banks, research academic laboratories, and home care settings. Hospitals clinics accounted for the largest share of the global market by end user.
“In 2021, North America accounted for the largest share of the immunoassay market ”
The global global market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Rest of the World, and Latin America. North America accounted for the largest share of the global immunoassay market in 2021. Factors such as the the availability of government funds, the growing use of immunoassays in clinical diagnostics, and the presence of key players in the region are contributing to the large share of this regional segment.
To know about the assumptions considered for the study, download the pdf brochure
The immunoassay market is dominated by players such as Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany).
Immunoassay Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$ 40.2 billion |
|
Estimated Value by 2027 |
$ 49.6 billion |
|
Growth Rate |
Poised to grow at a CAGR of 4.3% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Product, Technology, Specimen, Application, End User, and Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the immunoassay market into the following segments and subsegments:
Immunoassay Market By Product
-
Reagents & Kits
- ELISA Reagents & Kits
- Rapid Test Reagent & Kits
- ELISpot Reagent & Kits
- Western Blot Reagent & Kits
- Other Reagent & Kits
-
Analyzers
-
By Type
- Open-ended Systems
- Closed-ended Systems
-
By Purchase Mode
- Rental Purchase
- Outright Purchase
-
By Type
Immunoassay Market By Technology
-
ELISA
-
By Generation
- Third-generation & Above
- Second-generation & Belo
-
By Generation
- Rapid Tests
- ELISpot
- Western Blotting
- Radioimmunoassays
- Other Technologies
Immunoassay Market By Specimen
- Blood
- Saliva
- Urine
- Other Specimens
Immunoassay Market By Application
- Infectious Diseases
- Endocrinology
- Oncology
- Bone & Mineral Disorders
- Cardiology
- Blood Screening
- Autoimmune Disorders
- Allergy Diagnostics
- Toxicology
- Newborn Screening
- Other Applications
Immunoassay Market By End User
- Hospitals & Clinics
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies and CROs
- Blood Banks
- Research & Academic Laboratories
- Home Care Settings
Immunoassay Market By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Immunoassay Market Developments
- In June 2022, Roche received Emergency Use Authorization from the FDA for the Cobas SARS-CoV- 2 Duo for use on the fully automated Cobas 6800/8800 Systems.
- In July 2021, Beckman Coulter entered into an agreement with Quidel Corporation to gain rights for the manufacturing, distribution, and sales of a BNP assay by Quidel for Beckman Coulter analyzers.
- In December 2020, Abbott received US FDA EUA for its BinaxNOW COVID-19 Ag Card Rapid Test.
Frequently Asked Questions (FAQs):
What is the size of Immunoassay Market ?
The global Immunoassay Market boasts a total value of $40.2 billion in 2022 and is projected to register a growth rate of 4.3% to reach a value of $49.6 billion by 2027.
Why is Immunoassay Market Growing?
Market growth is driven by the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, and growth in the biotechnology and biopharmaceutical industries.
Who all are the prominent players of Immunoassay Market ?
The immunoassay market is dominated by players such as Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany). .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 44)
1.1 STUDY OBJECTIVES
1.2 IMMUNOASSAY MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 IMMUNOASSAY MARKET SCOPE
FIGURE 1 IMMUNOASSAY MARKET
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 48)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 IMMUNOASSAY MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 5 IMMUNOASSAY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 6 IMMUNOASSAY MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 IMMUNOASSAY MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 IMMUNOASSAY MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 59)
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION)
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 64)
4.1 MARKET OVERVIEW
FIGURE 15 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS— KEY DRIVERS OF MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY PRODUCT & COUNTRY (2021)
FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3 MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 17 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 MARKET: GEOGRAPHIC MIX
FIGURE 18 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 Immunoassay Market OVERVIEW (Page No. - 68)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.1.1 Increasing use of immunoassays in oncology
TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020
TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020
5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics
5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications
TABLE 5 DETECTION OF DRUGS BY URINE TESTING
5.2.1.1.4 Growing geriatric population
FIGURE 22 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.2 Advancements in systems and technologies
5.2.1.3 Growth in biotechnology and biopharmaceutical industries
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
TABLE 6 RECENT WAIVERS OF MARKET PRODUCTS
5.2.1.5 Supportive government policies
5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables
5.2.2.2 Technical hurdles of immunoassay kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics
TABLE 7 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED
5.2.3.3 Development of condition-specific biomarkers and tests
TABLE 8 NEW TESTS LAUNCHED BY KEY PLAYERS
5.2.3.4 Integration of microfluidics in immunoassays
TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS
5.2.3.5 Improving immunoassay diagnostic technologies
5.2.4 CHALLENGES
5.2.4.1 Design challenges, complexities, and quality of antibodies
5.2.4.2 Dearth of skilled professionals
5.2.4.3 Unfavorable reimbursement scenario
5.2.4.4 Financial hurdles faced by physicians
5.3 REGULATORY OVERVIEW
5.3.1 US
TABLE 10 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
5.3.2 CANADA
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.3.3 EUROPE
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
5.3.4 JAPAN
5.3.4.1 Japan: Regulatory process for IVD devices
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.5 CHINA
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.6 INDIA
5.3.6.1 India: Regulatory process for IVD devices
5.3.7 INDONESIA
TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.3.8 RUSSIA
TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.3.9 SAUDI ARABIA
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.10 MEXICO
5.3.10.1 Mexico: Regulatory process for IVD devices
TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.11 BRAZIL
5.3.11.1 Brazil: Regulatory process for IVD devices
5.3.12 SOUTH KOREA
TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.13 MIDDLE EAST
5.3.14 AFRICA
5.4 TECHNOLOGY ANALYSIS
TABLE 20 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
TABLE 21 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN MARKET
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS
TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION)
5.6 PATENT ANALYSIS
5.7 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS OF MARKET
FIGURE 27 ECOSYSTEM ANALYSIS OF MARKET
5.9.1 ROLE IN ECOSYSTEM
5.9.2 KEY PLAYERS OPERATING IN MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 24 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
5.10.1 DEGREE OF COMPETITION
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT FROM SUBSTITUTES
5.10.5 THREAT FROM NEW ENTRANTS
5.11 KEY CONFERENCES & EVENTS IN 2022
TABLE 25 LIST OF CONFERENCES & EVENTS
5.12 PRICING ANALYSIS
TABLE 26 IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.13.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 28 KEY BUYING CRITERIA, BY END USER
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15 SCENARIO-BASED MARKET ASSESSMENT
5.15.1 MARKET FORECAST
FIGURE 30 PESSIMISTIC SCENARIO
FIGURE 31 OPTIMISTIC SCENARIO
FIGURE 32 REALISTIC SCENARIO
6 IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 111)
6.1 INTRODUCTION
TABLE 29 MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 30 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET
TABLE 31 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.1 ELISA REAGENTS & KITS
6.2.1.1 Wide usage in basic research and high-throughput screening
TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.2 RAPID TEST REAGENTS & KITS
6.2.2.1 High demand for rapid test reagents & kits in remote areas to drive growth
TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.3 ELISPOT REAGENTS & KITS
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive demand
TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.4 WESTERN BLOT REAGENTS & KITS
6.2.4.1 Gold standard for result confirmation promotes Western blotting reagents & kits
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5 OTHER REAGENTS & KITS
TABLE 37 OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 ANALYZERS
TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET
TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
TABLE 40 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3.1.1 Open-ended systems
6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1.2 Closed-ended systems
6.3.1.2.1 High precision and automation are key features of closed-ended systems
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
TABLE 43 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
6.3.2.1 Rental purchase
6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental
TABLE 44 RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2.2 Outright purchase
6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs
TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 127)
7.1 INTRODUCTION
TABLE 46 MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 ELISA
TABLE 47 KEY ELISA SYSTEMS AVAILABLE IN MARKET
TABLE 48 MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION)
7.2.1 ELISA MARKET, BY GENERATION
TABLE 49 MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
7.2.1.1 Third-generation & above
7.2.1.1.1 Third- & fourth-gen ELISA show high specificity and accuracy
TABLE 50 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.1.2 Second-generation & below
7.2.1.2.1 Cost-effectiveness of first- and second-generation tests supports their use
TABLE 51 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2 ELISA MARKET, BY TYPE
TABLE 52 MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
7.2.2.1 CLIA
7.2.2.1.1 CLIA holds largest share of ELISA market, by type
TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2.2 IFA
7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens
TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2.3 Colorimetric immunoassays
7.2.2.3.1 Introduction of advanced techniques will support market growth
TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 RAPID TESTS
7.3.1 WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH
TABLE 56 KEY RAPID TESTS AVAILABLE IN MARKET
TABLE 57 MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION)
7.4 WESTERN BLOTTING
7.4.1 WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH
TABLE 58 WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
TABLE 59 MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION)
7.5 ELISPOT
7.5.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS
TABLE 60 MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION)
7.6 OTHER TECHNOLOGIES
TABLE 61 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
8 IMMUNOASSAY MARKET, BY SPECIMEN (Page No. - 141)
8.1 INTRODUCTION
TABLE 62 MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
8.2 BLOOD
8.2.1 HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH
TABLE 63 MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.3 SALIVA
8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH
TABLE 64 MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.4 URINE
8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS
TABLE 65 MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.5 OTHER SPECIMENS
TABLE 66 MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
9 IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 147)
9.1 INTRODUCTION
TABLE 67 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 68 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS
TABLE 69 MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.4 CARDIOLOGY
9.4.1 HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH
TABLE 70 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS
TABLE 71 MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5 AUTOIMMUNE DISORDERS
9.5.1 RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 72 MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS
TABLE 73 MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
9.7 ONCOLOGY
9.7.1 RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH
TABLE 74 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 75 MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.8 BONE & MINERAL DISORDERS
9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 76 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS
TABLE 77 MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
9.9 TOXICOLOGY
9.9.1 DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY
TABLE 78 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS
TABLE 80 MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.10 BLOOD SCREENING
9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS
TABLE 81 MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR
TABLE 82 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING
TABLE 83 MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.12 OTHER APPLICATIONS
TABLE 84 MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
10 IMMUNOASSAY MARKET, BY END USER (Page No. - 164)
10.1 INTRODUCTION
TABLE 85 MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH
TABLE 86 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS
TABLE 87 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY
TABLE 88 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION)
10.5 HOME CARE SETTINGS
10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH
TABLE 89 MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION)
10.6 BLOOD BANKS
10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING
TABLE 90 MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION)
10.7 RESEARCH & ACADEMIC LABORATORIES
10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH
TABLE 91 MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
11 IMMUNOASSAY MARKET, BY REGION (Page No. - 173)
11.1 INTRODUCTION
TABLE 92 MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US holds largest share in North American market
TABLE 104 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 105 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 108 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109 US: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 110 US: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 US: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 112 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Initiatives undertaken by government bodies to support growth of market in Canada
TABLE 114 CANADA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 115 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 118 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 119 CANADA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 120 CANADA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 CANADA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 122 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 123 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 124 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 126 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 129 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 EUROPE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 131 EUROPE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 EUROPE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany holds largest share of EU immunoassay market
TABLE 135 GERMANY: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 136 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 139 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 140 GERMANY: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 141 GERMANY: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 142 GERMANY: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 143 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 144 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 ITALY
11.3.2.1 Growing geriatric population and increasing support for research to support market growth
TABLE 145 ITALY: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 146 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 149 ITALY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 150 ITALY: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 151 ITALY: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 ITALY: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 153 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 154 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising use of POC testing and favorable reimbursement policies make France a lucrative market
TABLE 155 FRANCE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 156 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 159 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 160 FRANCE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 161 FRANCE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 FRANCE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 163 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 164 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 SPAIN
11.3.4.1 Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market
TABLE 165 SPAIN: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 166 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 169 SPAIN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 170 SPAIN: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 171 SPAIN: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 SPAIN: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 173 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 174 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 UK
11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive market in UK
TABLE 175 UK: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 179 UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 UK: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 181 UK: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 182 UK: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 183 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 184 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 RUSSIA
11.3.6.1 Lack of reimbursement and delays in approval may hinder market growth
TABLE 185 RUSSIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 186 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 189 RUSSIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 190 RUSSIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 191 RUSSIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 192 RUSSIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 193 RUSSIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 194 RUSSIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 195 REST OF EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 196 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 199 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 200 REST OF EUROPE: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 201 REST OF EUROPE: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 202 REST OF EUROPE: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 203 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 204 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 34 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 205 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 206 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 207 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 210 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 211 ASIA PACIFIC: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 212 ASIA PACIFIC: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 ASIA PACIFIC: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 214 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 215 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Investments in healthcare technology and research to support growth in Japan
TABLE 216 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 217 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 220 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 221 JAPAN: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 222 JAPAN: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 223 JAPAN: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 224 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 225 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Opportunities for growth in China hampered by long product approval and registration processes
TABLE 226 CHINA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 227 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 230 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 231 CHINA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 232 CHINA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 233 CHINA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 234 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 235 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India
TABLE 236 INDIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 237 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 240 INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 241 INDIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 242 INDIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 243 INDIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 244 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 245 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Growing disease incidence and technological development drive market growth
TABLE 246 AUSTRALIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 247 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 250 AUSTRALIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 251 AUSTRALIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 252 AUSTRALIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 253 AUSTRALIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 254 AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 255 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Rising healthcare spending and investments in research fuel market growth
TABLE 256 SOUTH KOREA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 257 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 260 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 261 SOUTH KOREA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 262 SOUTH KOREA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 263 SOUTH KOREA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 264 SOUTH KOREA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 265 SOUTH KOREA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.6 INDONESIA
11.4.6.1 Indonesia has become a promising market and growth hotspot for foreign investors
TABLE 266 INDONESIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 267 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 270 INDONESIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 271 INDONESIA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 272 INDONESIA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 273 INDONESIA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 274 INDONESIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 275 INDONESIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 276 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 277 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 280 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 281 REST OF ASIA PACIFIC: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 282 REST OF ASIA PACIFIC: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 283 REST OF ASIA PACIFIC: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 284 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 285 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 286 LATIN AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 287 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 288 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 291 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 292 LATIN AMERICA: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 293 LATIN AMERICA: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 LATIN AMERICA: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 295 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 296 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Brazil was largest market for immunoassays in LATAM
TABLE 297 BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS
TABLE 298 BRAZIL: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 299 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 302 BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 303 BRAZIL: MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 304 BRAZIL: MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 BRAZIL: MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 306 BRAZIL: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 307 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Growing lab consolidation to reduce number of labs in Mexico
TABLE 308 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 309 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 312 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 313 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 314 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 316 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 317 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 318 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 319 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 322 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 323 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 324 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 325 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 326 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 327 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
TABLE 328 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 336 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 337 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 318)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS
12.3 REVENUE ANALYSIS
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
TABLE 338 IMMUNOASSAY MARKET: DEGREE OF COMPETITION
FIGURE 36 MARKET SHARE ANALYSIS, 2021
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
12.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
12.7 COMPANY FOOTPRINT ANALYSIS
TABLE 339 COMPANY FOOTPRINT
TABLE 340 COMPANY PRODUCT FOOTPRINT
TABLE 341 COMPANY REGIONAL FOOTPRINT
12.8 COMPETITIVE BENCHMARKING
TABLE 342 IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 343 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2018–2022
12.9.2 DEALS
TABLE 344 IMMUNOASSAY MARKET: DEALS, 2018–2022
12.9.3 OTHER DEVELOPMENTS
TABLE 345 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2018–2022
13 COMPANY PROFILES (Page No. - 332)
13.1 MAJOR PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 ABBOTT LABORATORIES
TABLE 346 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 39 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.2 ROCHE DIAGNOSTICS
TABLE 347 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 40 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
13.1.3 SIEMENS HEALTHINEERS AG
TABLE 348 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.4 DANAHER CORPORATION
TABLE 349 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
13.1.5 THERMO FISHER SCIENTIFIC INC.
TABLE 350 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
13.1.6 PERKINELMER, INC.
TABLE 351 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 44 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.7 BECTON, DICKINSON AND COMPANY
TABLE 352 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.8 DIASORIN S.P.A.
TABLE 353 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021)
13.1.9 BIO-RAD LABORATORIES, INC.
TABLE 354 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
13.1.10 QUIDEL CORPORATION
TABLE 355 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 48 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
13.1.11 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
TABLE 356 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
FIGURE 49 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
13.1.12 BIOMÉRIEUX
TABLE 357 BIOMÉRIEUX: BUSINESS OVERVIEW
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2021)
13.1.13 QIAGEN
TABLE 358 QIAGEN: BUSINESS OVERVIEW
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2021)
13.1.14 SYSMEX CORPORATION
TABLE 359 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
13.1.15 AGILENT TECHNOLOGIES
TABLE 360 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
13.1.16 MINDRAY MEDICAL INTERNATIONAL COMPANY
TABLE 361 MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MERCK KGAA
13.2.2 MERIDIAN BIOSCIENCE
13.2.3 BIO-TECHNE
13.2.4 CELLABS
13.2.5 ABNOVA CORPORATION
13.2.6 J. MITRA & CO.
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES)
13.2.8 CELL SCIENCES
13.2.9 ENZO BIOCHEM
13.2.10 CREATIVE DIAGNOSTICS
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
13.2.12 ELABSCIENCE
13.2.13 WAK-CHEMIE MEDICAL
13.2.14 SERA CARE
13.2.15 EPITOPE DIAGNOSTICS
13.2.16 KAMIYA BIOMEDICAL COMPANY
13.2.17 GYROS PROTEIN TECHNOLOGIES
13.2.18 TRIVITRON HEALTHCARE
13.2.19 INBIOS INTERNATIONAL, INC.
14 APPENDIX (Page No. - 415)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the immunoassay market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the immunoassay market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the immunoassay market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Immunoassay Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global immunoassay market on the basis of product, technology, specimen, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall immunoassay market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to five main regions—North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America.
- To strategically profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as acquisitions, product launches & approvals, agreements, acquisitions, and collaborations in the immunoassay market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographic Analysis
- Further breakdown of the RoE, RoAPAC, and RoLATAM immunoassay markets
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Growth opportunities and latent adjacency in Immunoassay Market
What are the major revenue pockets in Immunoassay Market?
What are the latest growth trends in immunoassay industry?
Which segment ot provide highest revenue expansion opportynity?